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Protein-templated fragment ligations have been established as a powerful method for the
assembly and detection of optimized protein ligands. Initially developed for reversible liga-
tions, the method has been expanded to irreversible reactions enabling the formation of
super-additive fragment combinations. Here, protein-induced Mannich ligations are dis-
covered as a biocatalytic reaction furnishing inhibitors of the transcription factor STAT5.
STAT5 protein catalyzes multicomponent reactions of a phosphate mimetic, formaldehyde,
and 1H-tetrazoles yielding protein ligands with greatly increased binding afﬁnity and ligand
efﬁciency. Reactions are induced under physiological conditions selectively by native STAT5
but not by other proteins. Formation of ligation products and (auto-)inhibition of the reaction
are quantiﬁed and the mechanism is investigated. Inhibitors assembled by STAT5
block speciﬁcally the phosphorylation of this protein in a cellular model of acute myeloid
leukemia (AML), DNA-binding of STAT5 dimers, expression of downstream targets of the
transcription factor, and the proliferation of cancer cells in mice.
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In protein-templated fragment ligations, proteins catalyze theformation of ligands with enhanced binding afﬁnity frombound reactive fragments, thereby integrating chemical
synthesis of protein ligands and modulation of protein activity in
one single step1–6. The chemical space accessible by protein-
templated reactions, however, is still strongly limited. Whereas
most applications so far have employed reversible7–10, i.e.,
dynamic ligation reactions, few reactions have been used for the
irreversible11–15 formation of stable protein ligands by protein-
templated reactions, mostly employing dipolar cycloaddition
reactions13,14. Recently, amide bonds, a privileged fragment
linkage in bioactive molecules, have been accessed by protein-
templated chemistry16. Evidently, it would be a major expansion
of the chemical space populated by protein-dependent reactions,
if multicomponent reactions could be employed for ligand for-
mation—possibly exploiting alternative mechanisms9.
Here, Mannich ligations, three-component reactions of an
amine, aldehyde, and N- or C-nucleophile, are investigated as
protein-catalyzed reactions for discovering protein ligands. As a
target, the transcription factor STAT5 (STAT= signal transdu-
cers and activators of transcription) is selected representing a
central hub in the signaling of numerous cancer cell types. A
small heterocyclic phosphate-mimetic binding to STAT5 with low
afﬁnity is discovered from a fragment screen and used as a
starting point for fragment expansion using protein-induced
multicomponent reactions. Mannich ligation products with
improved afﬁnity for STAT5 are assembled by the protein and
selectivity, pH-dependence, and the biocatalytic mechanism of
this protein-induced reaction are investigated. Furthermore,
selectivity and functional efﬁcacy of the inhibitors are validated
for isolated proteins, in complex cell lysates, in living cells and
ﬁnally in mice in order to evaluate the functional potential of
protein ligands generated by protein-induced ligation.
Results
Target selection. The transcription factor STAT5 was selected as
a target owing to its central role in the signaling of numerous
cancer cell types17,18. STAT5 is expressed in two closely related
forms, STAT5a and b, with 94% identity of the amino-acid
sequence. STAT5 contains an SH2 domain, which is responsible
for the binding of the protein to phosphotyrosine-containing
peptide sequences of kinases, resulting in the phosphorylation at
tyrosine 694/699. Phospho-STAT5 dimerizes via its SH2 domain
and translocates into the nucleus19. There, p-STAT5 dimers bind
to genomic promoter sequences inducing the transcription of
target genes. In consequence, ligands of STAT-SH2 domains are
able to suppress STAT signaling and have been recognized as
potential anticancer drugs. STATs, however, have been described
as difﬁcult pharmacological targets20. Although highly potent
peptide ligands have been reported for the STAT-SH2
domains21,22, these phosphopeptide mimetics usually fail to
provide signiﬁcant cellular activity. Several cellularly active small
molecule inhibitors of STAT5 have been developed as well,
however, none of these have been based on protein-induced
reactions yet23–25.
Discovery and validation of a phosphate-mimetic fragment.
Binding of fragments to the recombinantly expressed STAT5b-
SH2 domain fused to maltose-binding protein (MBP) as afﬁnity
tag was recorded by measuring ﬂuorescence polarization (FP) of
the carboxyﬂuoresceine-labeled phosphotyrosine octapeptide
1 (KD= 55 nM) (Fig. 1a)21. A collection of 17,000 fragments and
fragment combinations composed in accordance with the sub-
structure composition of the World Drug Index (WDI)26 was
screened for inhibiting the phosphopeptide-STAT5b interaction.
Primary amine fragments were tested in the FP assay in the
presence of electrophilic phosphotyrosine mimic 2 as described
earlier for protein tyrosine phosphatases (PTP) in order to dis-
tinguish secondary site binders that enhance the inhibition of
2 from inhibitors that are not affected by 25,21. From the second
group, one fragment, 4-amino-furazan-3-carboxylic acid 3 (M=
129 g mol−1, Fig. 1a) displayed a KD value of 420 µM, corre-
sponding to the ligand efﬁciency of 2.1 kJ mol−1 per non-
hydrogen atom, higher than that of the nanomolar phospho-
peptide 1, the phosphotyrosine-mimetic 2, and the best reported
STAT5 inhibitors23–25. Ligands with such high ligand efﬁciency
are rather found for enzymatic binding pockets than for
protein–protein interaction sites and thus fragment 3 was selected
for further validation27. Binding of 3 to STAT5b-SH2 was con-
ﬁrmed using the thermoﬂuor assay28,29, a thermal shift assay
(TSA), as an independent biophysical assay. Binding of fragment
3 augmented the melting point of STAT5 by ΔTm of 3 °C (Sup-
plementary Figure 1). Potential binding modes of the phospho-
tyrosine 2 and the fragment hit 3 were scrutinized using a
homology model of STAT5b derived from the crystal structure of
STAT5a (PDB:1Y1U [https://doi.org/10.2210/pdb1Y1U/pdb]) for
molecular docking (Fig. 1b, c)30. The phosphotyrosine binding
site in the STAT5-SH2 domain is shallow compared with the
deeper binding pockets of PTP31,32, coordinating phenyl phos-
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Fig. 1 Discovery of phosphate-mimetic fragment 3. a Fluorescently labeled phosphotyrosine peptide 1 was used in an FP assay for the screening of a
fragment library furnishing 4-amino-furazan-3-carboxylic acid 3 as a phosphate-mimetic21. Phosphotyrosine-mimetic fragment 4-formyl-phenyl phosphate
2 was employed to investigate fragment hits for second site binding. b–c Molecular docking results of fragments 2 and 3 into homology model of human
STAT5b-SH2 domain, generated from the published structure of STAT5a (PDB accession codes, 1Y1U [http://dx.doi.org/10.2210/pdb1Y1U/pdb])30.
Hydrogen bonds with key residues in the hydrophilic binding pocket of the STAT5-SH2 domain were illustrated as red dashed lines
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a result, the benzene ring of 2 is not buried in a cavity like in the
case of PTPs but rather exposed to the solvent at the protein
surface. Binding of fragment 3 is mediated by the Coulomb
interaction between the carboxylate anion and the cation of
protonated Arg618 and H-bonds involving Arg618, Ser622, and
Asn642.
Fragment expansion via protein-induced Mannich ligations.
First, the discovered phosphate-mimetic 3 was expanded by
amidation (Fig. 2a), a reaction recently introduced to protein-
templated fragment ligations16. The N-acetyl derivative 4 and all
other tested amides including 5, however, were inactive in the FP
assay. In order to reduce the steric demand from a carbonyl to the
more ﬂexible methylene linkage, the Mannich ligation was
investigated as fragment expansion method (Fig. 2b). Fragment
3 was found to react readily with formaldehyde (FA) and various
N-heterocycles in aqueous buffer at pH 5.0 at room temperature
yielding Mannich ligation products, whereas no reaction was
observed without protein at pH 7.4. In order to implement
protein-dependent Mannich ligations, the compatibility of the
reaction with the protein MBP-STAT5b-SH2 and with the FP
assay was investigated. 3-(N-Morpholino)-propane sulfonic acid
(MOPS, 50 mM, pH 7.4) was used as a buffer containing no
primary and secondary amines that could interfere with the
reaction. FP of MBP-STAT5b-SH2 (125 nM) with peptide 1 (10
nM) was recorded in the presence of increasing concentrations of
FA at pH 7.4. No change of FP was observed at concentrations up
to 250 µM FA, whereas at higher concentrations, FP values
increased considerably (Fig. 3a). Likewise, up to 250 µM no effect
of FA on the melting point of STAT5b-SH2 was recorded in the
TSA, although higher FA concentrations reduced the intensity of
the ﬂuorescence signal, suggesting interference of FA with the
ﬂuorescent dye (Fig. 3b). For in situ Mannich ligation assays,
fragment 3 was incubated with one hetaryl nucleophile and FA
(all 250 µM) per microtiter plate-well in water resulting in pH 5.0.
After 12 h incubation at room temperature, protein MBP-
STAT5b (125 nM in 50 mM MOPS buffer pH 7.4) with the pep-
tide probe 1 were added and further incubated for 15 min before
FP was recorded. Several of the added heterocycles led to sub-
stantially decreased FP values—suggesting the formation of a
Mannich ligation product as inhibitor of STAT5b with increased
afﬁnity. Active Mannich ligation products were re-synthesized,
puriﬁed, and tested in the FP assay (Fig. 2b, Supplementary
Figures 11–13). Remarkably, the addition of ﬁve-membered
N-heterocycles (“azoles”) to the formimine of fragment 3 led to
strongly enhanced inhibition of STAT5b. The 1,2,3-triazol-1-yl
product 6 as well as the benzo-1,2,3-triazol-1-yl 7 increased the
afﬁnity by a factor of > 2, pyrazol-1-yl 8 > threefold, 1,2,4-triazol-
1-yl 9 > ninefold and tetrazol-1-yl 10 300-fold resulting in a KI of
1.4 µM (Supplementary Figure 2). The reaction with 5-substituted
tetrazoles yielded strongly active inhibitors 11–17, some even
with submicromolar afﬁnities, including 4-(5-phenyl-tetrazol-1-
yl-methylamino)-furazane-3-carboxylate 11 (1.4 µM), 5-(3-tri-
ﬂuoromethyl-phenyl)- 12 (0.9 µM), 5-(3-ﬂuorophenyl) 13
(0.6 µM), 5-benzyl 16 (2.9 µM), and 5-biphenyl 17 (0.8 µM). Esters
of the furazane carboxylic acid (18, 19) were prepared as prodrug
derivatives. 4-(Tetrazolyl-1-methylamino)-furazan-3-carboxylic
acid 10 is the STAT5 inhibitor with the highest ligand efﬁciency
of 2.23 kJ mol−1 per non-hydrogen atom. All starting azoles like
tetrazole 25 were completely inactive at concentrations of 5 mM,
thus the inhibitors constitute examples of super-additive frag-
ment combinations. As a consequence, the observed
protein-dependent ligation reaction did not proceed as a protein-
templated reaction, that requires the binding of both reacting











































































6: 191 μM 7: 189 μM 8: 122 μM 9: 48 μM
10:1.4 μM 12: 0.9 μM 13: 0.6 μM 14: 3.0 μM





































































































Fig. 2 Expansion of fragment 3 through protein-induced reactions. a Amidation of 3 yielded compounds 4 and 5, which were inactive in the FP assay.
b Mannich ligation was investigated as an alternative fragment expansion method to obtain the active compounds 6–19 containing a linker with reduced
steric hindrance and better structural ﬂexibility
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Mechanistic analysis of the protein-induced reactions. Protein-
catalyzed reactions of fragment 3 with FA and 1H-tetrazole 25
were investigated by using the binding assays (FP, TSA), and
high-performance liquid chromatography-mass spectrometry
(HPLC-MS) analysis. Incubation of fragments 3 and 25 (250 µM
each) with MBP-STAT5b-SH2 (250 nM) with increasing con-
centrations of FA at pH 7.4 led to decreased FP values, suggesting
the formation of an inhibitor (Fig. 3c). The protein-induced
formation of a STAT5 inhibitor was conﬁrmed in the TSA:
Incubation of fragments 3 and 25 with increasing concentrations
of FA and the protein resulted in a shift of the protein's melting
point ΔTm by 7 °C (Fig. 3d). High-resolution HPLC-QTOF-MS
analysis was employed to quantify Mannich ligation product 10
formed with or without protein present (Fig. 3e). At pH 7.4,
absolutely no inhibitor was formed from 3, 25, and FA, if
MBP-STAT5-SH2 protein was not present (trace 1). With 250 nM
MBP-STAT5-SH2 in the buffer at pH 7.4, 432 nM of 10 were
formed over 24 h (average of three independent experiments).
The protein-dependent reaction was saturated after 24 h, no
signiﬁcant changes in product concentration were observed
between 24 and 48 h reaction time—suggesting product inhibi-
tion of the ligation reaction. Addition of phosphopeptide 1 or
inhibitor 16 to the protein-induced reaction suppressed the for-
mation of 10 completely or partly in a concentration-dependent
manner (traces 3–6). If instead of the MBP-STAT5-SH2 protein
only the protein tag MBP (1 µM) or the catalytic domains of
tyrosine phosphatases PTP1B or SHP2 (250 nM) were added, no
product was formed at all (traces 7,9,10). In contrast, incubation
of reagents 3, 25, and FA at pH 5.0 led with or without protein to
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3 + 25 + FApH 5.0 w/o protein
3 + 25 + FA + GST-STAT3
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3 + 25 + FA + PTP1B





3 + 25 + FA + STAT5b-N642A0 nM
ΔTm = 7°C
Fig. 3 Assembly of STAT5 inhibitor 10 through protein-induced Mannich ligations. a FA was tolerated at up to 250 µM in the FP assay of MBP-STAT5b-SH2
(n= 3). b FA did not affect the STAT5b protein stability in the TSA at≤ 250 µM (data shown are one representative of n= 3). c Protein-induced formation
of 10 in the FP assay with increasing FA concentrations (n= 3). d Protein-induced formation of 10 from fragments 3 and 1H-tetrazole 25 with increasing FA
concentrations in the TSA (ΔTm= 7 °C) (data shown are one representative of n= 3). e Formation of 10 detected in the HPLC-QTOF-MS. 1: No formation
of 10 from FA, fragments 3 and 25 (all 250 µM) at pH 7.4 in MOPS buffer without protein. 2: Protein-induced formation of compound 10 with protein MBP-
STAT5b-SH2 (250 nM) at pH 7.4. 3–6: Inhibition of protein-induced formation of 10 by peptide 1 (3,4) or inhibitor 16 (5,6). 7,8: No formation of compound
10 in the presence of Maltose Binding Protein (1 µM) or GST-STAT3 (250 nM). 9–11: Compound 10 was not formed in the presence of phosphatases, SHP2
(250 nM) and PTP1B (250 nM) nor in the presence of mutant STAT5b-N642A at pH 7.4 in MOPS buffer. 12: Formation of compound 10 at pH 5.0 without
protein. Data shown are one representative example of n= 3. f 3D-binding model of the STAT5b:10 complex. Hydrogen bonds are illustrated as red dashed
lines. g, Mechanism of the protein-induced formation of 10 from 3 with FA and 25 (R=H). (i) Binding of 3 via Arg618, Ser622, and Asn642, activation of
FA with Asn642. (ii) Activation of the forminium cation of 3, coordination of the incoming tetrazolium anion of 25 by Asn642 leads to formation of
Mannich ligation product 10 (iii). Error bars denote mean ± S.D
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background reaction (trace 12). Similar data were obtained for the
protein-dependent reaction of fragments 3, FA, and benzyl-
tetrazole 26 although traces of a background reaction were
observed in this case (Supplementary Figure 3). In contrast, no
protein-dependent reaction was observed when replacing the 1H-
tetrazoles by 1,2,4-triazole (Supplementary Figure 3).
Molecular docking suggested that the large increase in binding
afﬁnity of compound 10 was contributed by expansion of the
binding interaction into the adjacent amphiphilic pocket contain-
ing residues Trp641, Leu643, and Met639 via hydrophobic
contacts. The H-bond, between the 4-amino group of 10 and the
carbonyl of Asn642 was retained and possibly enforced by the
higher polarity of the NH-bond in 10 (Fig. 3f). An additional
H-bond was proposed by BINding ANALyzer (BINANA)
between the tetrazole ring and the amide-NH2 of Asn642 and
strengthened the binding of compound 10 in the binding
pocket18,23,33,34. In order to challenge the postulated importance
of Asn642 for the reactivity of fragment 3 with STAT5b-SH2, the
fragment ligation of 3, FA, and 1H-tetrazole at pH 7.4 was
investigated with GST-STAT3, a protein without Asn in the
otherwise similar phosphotyrosine recognition site (Fig. 3, trace
8). With STAT3 instead of STAT5b absolutely no fragment
ligation product was formed. In addition, the mutant MBP-
STAT5b-SH2 N642A was generated by site-directed mutagenesis.
The mutant protein displayed strongly reduced binding afﬁnity to
peptide 1 with KD of ca. 5 µM (instead of 55 nM for the wildtype)
(Supplementary Figure 2g). Binding of the peptide was inhibited
by compound 10 with an IC50 of 30 µM (instead of 1.5 µM for the
wildtype) (Supplementary Figure 2h). Accordingly, the conditions
of the fragment ligation reaction yielded no product with the
mutant protein as well. Plausibly, the side chain carbonyl group of
Asn642 binds to the amino group of compound 3 via accepting
an H-bond (Fig. 3g). As a result, the amide-NH2 of Asn642 is free
to coordinate and activate the incoming FA as an H-bond donor,
leading to the formation of the formiminium derivative of 3,
which is again stabilized by its H-bond to the Asn-carbonyl. Next,
the amide-NH2 could coordinate the incoming 1H-tetrazolium
ion which reacts to the observed ligation product 10.
Speciﬁcity of STAT5 inhibitors. Compound 10 was tested with
closely related STAT3 and the catalytic domain of protein tyr-
osine phosphatase SHP2 (PTPN10) and at concentrations up to
1 mM no binding or inhibition was observed (Supplementary
Figure 4). Next, phosphorylated STAT-dimers were extracted
from nuclei of BaF3/FLT3-ITD cells and binding of STAT1, 3, 5a,
and 5b to DNA was detected using an enzyme-linked immuno-
sorbent assay (ELISA) speciﬁc for the respective protein-DNA-
complexes. Compounds 3, 10, and 16 inhibited formation of the
DNA complex of STAT5a and STAT5b, but not of STAT1 and
STAT3 (Fig. 4b). Likewise, inhibition of the STAT5:DNA com-
plex by compound 10 was detected in the electro mobility shift
assay (EMSA) (Fig. 4c). The speciﬁcity of compound 10 was
further investigated in complex cell lysates using cellular thermal
shift assays (CETSA) (Fig. 4d)35. Compound 10 bound to isolated
MBP-STAT5b-SH2 shifting the melting temperature (Tm) by 9 °C
(Fig. 4a). BaF3/FLT3-ITD cell lysates were incubated with 10 and
exposed to a temperature gradient from 43–73 °C36. Supernatants
were analyzed by gel electrophoresis and immunoblotting was
performed with STAT5a/b antibodies. Inhibitor 10 shifted the
melting temperatures of STAT5a/b by 5 and 8 °C, respectively,
indicating the thermal stabilization of STAT5 proteins through
ligand binding in cell lysates (Fig. 4d, e).
The speciﬁc interaction of inhibitor 10 with STAT5 was further
challenged by interfering with the photo-crosslinking of STAT5b-
SH2 and the dual-labeled STAT5-binding peptide 5-CF-K(biotin)
GpcFLSLPPW-NH2 27 (CF= carboxyﬂuorescein, pcF= phos-
phono-carboxy-phenylalanine)21. Peptide 27 was demonstrated
to photo-crosslink STAT5b after being exposed to UV irradiation
at 365 nm and 10 suppressed the photo-crosslinking in a
concentration-dependent manner (Supplementary Figure 4).
When peptide 27 was incubated with BaF3/FLT3-ITD cell lysate,
irradiated for 15 min at 4 °C and subjected to pull-down using
avidin beads, compound 10 repressed STAT5-crosslinking by
displacing peptide 27 competitively in the complex lysate
(Fig. 4f).
Validation of STAT5 inhibitors in living cells and animals. The
biological activity of inhibitors was studied in a cellular disease
model using the murine pro-B-cell line BaF3 stably transfected
with the internal tandem duplication (ITD) mutation of the
human FLT3 receptor (FLT3-ITD)37. In these cells, STAT5 is
constitutively phosphorylated without cytokine activation. As the
FLT3-ITD mutation is found in 35% of AML patients, it can be
considered as a relevant model for this disease38.
At ﬁrst, STAT5 phosphorylation at tyrosine residues (Tyr694/
Tyr699) was investigated. 5-Aryl-substituted derivatives like
11–13 could not be tested in cells as they precipitated in buffer.
Compounds 10, 16, and 18 were dissolved in dimethylsulphoxide
(DMSO) (20 mM) and added to BaF3/FLT3-ITD cells. After 6 h
cells were harvested to determine the level of STAT5 phosphor-
ylation using phosphotyrosine-speciﬁc antibodies. The strongest
inhibition was observed for compound 16 with > 50% reduction
of STAT5 phosphorylation at 25 µM (Fig. 5a). In contrast, the
phosphorylation of STAT5 was inhibited by 10 only with an IC50
value of > 100 µM. We suspected that the low cellular activity of 10
was hampered by low cellular uptake owing to its high polarity.
This suspicion was substantiated by the higher activity of ester
derivative 18, which might act as prodrug being activated by
intracellular esterases24,33,39. A time course experiment indeed
showed that compound 18 reduced STAT5 phosphorylation
steadily over 10 h (Supplementary Figure 5). Both compounds 16
and 18 had no effect on the overall expression of endogenous
STAT5 (Supplementary Figure 5).
Next, inhibition of gene transcription by 16 was determined.
BaF3/FLT3-ITD cells transfected with a dual ﬁreﬂy/Renilla
luciferase system were treated with 16 for 6 h and the activity
of the STAT5-transcribed luciferase reporter gene was found to
reduce signiﬁcantly in a dose-dependent manner (Fig. 5b).
Inhibition of the endogenous transcription of STAT5 target
genes by 16 and 18 was studied, too. BaF3/FLT3-ITD cells were
treated with inhibitors for 6 h, mRNA was harvested and
analyzed by quantitative RT-PCR. Transcription and protein
expression of three target genes of STAT5, Pim1 kinase, Bcl-xl,
and Cis, which play essential roles in cell cycle progression and
survival, was found to be strongly reduced (Fig. 5c, Supplemen-
tary Figure 5).
The effect of STAT5 inhibitors 10, 16, and 18 on the
proliferation of cancer cells carrying the common FLT3-ITD
mutation after 48 h was quantiﬁed by the Alamar Blue assay
(Fig. 5d). All three compounds showed a clear dose-dependent
inhibition of cell proliferation. For comparison, the compounds
were tested with four non-STAT5-dependent cell lines (HT-29,
COS-7, HeLa and MDA-MB-231) and here cytotoxicity was
negligible at up to 500 µM (Supplementary Figure 6). The
compounds also showed no effects on STAT3 phosphorylation
and on endogenous STAT3 expression (Supplementary Figures 5
and 6)25. The percentage of necrotic vs. apoptotic cells death after
treatment with 16 was studied by ﬂow cytometry staining with a
ﬂuorescent annexin-V conjugate and with propidium iodide (PI),
likewise reduced STAT5 phosphorylation was studied using a
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ﬂuorophor-conjugated anti-pSTAT5 antibody (PE-Cy7 Mouse
anti-STAT5, pY694, Fig. 5e).
Target speciﬁcity of compound 16 to STAT5 in living cells was
evaluated using isothermal dose–response ﬁngerprints (ITDRF)40,
a variation of CETSA experiments. BaF3/FLT3-ITD cells were
treated with 16 at concentrations between 0 and 100 µM for 6 h.
All samples were heated for 3 min to 60 °C, the denaturation
temperature based on the Tm curves in the CETSA experiment
(Fig. 4d, e), lyzed and immunoblotted with STAT5a/b antibodies.
The amount of STAT5 protein found in the blot was plotted
against logarithmic concentration of the inhibitor, indicating the
in-cell occupancy (OC50) of STAT5a/b of 63 and 28 µM,
respectively, correlating well with the inhibition of target
phosphorylation and cell proliferation (Fig. 5f, g).
Moreover, the synergistic effects of STAT5 inhibitor 16 with
the staurosporine-derived FLT3-inhibitor PKC412 were
investigated41,42. The receptor tyrosine kinase FLT3 and
especially the constitutively activated mutant FLT3-ITD have
been described to be responsible for the phosphorylation and,
thereby, overactivation of STAT5. Treatment of AML patients
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Fig. 4 Inhibitor 10 blocks STAT5 dimerization, DNA-binding, and is active in CETSA and photocrosslinking assays in cellular lysates. a 10 stabilizes
MBP-STAT5b-SH2 shifting the melting temperature (ΔTm) by 9 °C in the TSA (data shown are one representative example of n= 3). b 10 and 16 inhibit
formation of trimeric (STAT5b)2-DNA complexes in an ELISA (n= 3). c (i) 10 inhibits binding of STAT5 dimers, isolated from nuclear extracts of BaF3/
FLT3-ITD cells, to its target DNA in the electro mobility shift assay (EMSA) and (ii) shows selectivity for disrupting STAT5a,b-DNA complexes in the
TransAM® STAT family ELISA (n= 3). d–e 10 binds to STAT5a and STAT5b in complex cellular lysates as demonstrated by cellular TSA (CETSA), resulting
in shifted melting curves at 50 µM compared with vehicle (DMSO). Relative STAT5a and STAT5b band intensities were plotted against corresponding
incubation temperatures and ﬁtted to Boltzmann sigmoidal curve. The blue triangle represents DMSO and red circle represents compound 10 (n= 3).
f Binding of 10 to STAT5 in BaF3/FLT3-ITD cell lysate was determined by photo-crosslinking (n= 3). (i) The dual-labeled (carboxyﬂuorescein and biotin)
peptide probe 27 binds to STAT5 with submicromolar afﬁnity and photocrosslinked (ii) with target proteins by activating the 4-phosphoncarbonyl residue
that acts as a photoactive phosphotyrosine-mimetic. (iii) Cross-linked proteins can be isolated by biotin pull-down using Neutravidine beads. (iv)
Displacement of 27 (100 µM) by compound 10 (50 µM) in BaF3/FLT3-ITD cell lysates (1 mgml−1) resulted in signiﬁcantly reduced photo-crosslinking of
27 and STAT5 as demonstrated in the western blotting using STAT5 antibodies (right lane), whereas other biotinylated proteins were not reduced (middle
lane). For an uncropped image of c, d, e, f see Supplementary Figure 10. Error bars denote mean ± S.D. and p values are considered as follows: *p value <
0.05; **p value < 0.01; and ***p value < 0.001. Statistical analyses were performed using one-way ANOVA or the two-tailed Student’s t tests where
appropriate
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bearing the FLT3 mutation with PKC412 alone exhibited a
therapeutic effect, however, often led to major drawbacks such
as incomplete target inhibition and short-lived responses.
Therefore, combination treatment of leukemic cells with two
inhibitors, one targeting FLT3 and the other STAT5, can be a
promising strategy to enhance inhibition of STAT5 signaling,
overcome or prevent resistance toward kinase inhibitors and
improve treatment efﬁcacy38,41. MV-411 leukemic cells were
treated with concentrations of inhibitors resulting in 20% of cell
apoptosis individually as well as in combination. The combina-
tion of 16 and PKC412 resulted in a threefold increase in
annexin-V-staining corresponding to 60% apoptotic cells, in
decreased reporter gene expression, and in reduced STAT5
phosphorylation (Fig. 6a–d). Both compounds impaired
synergistically the cell proliferation after 48 h of treatment as
demonstrated by a Chou–Talalay combination index (CI) plot
(Fig. 6c)43. For example, the IC50 of compound 16 was reduced
threefold in the presence of 1.25 nM (IC10) of PKC412.
Finally, the inhibitory effect of 16 was examined in a murine
xenograft model of leukemia. Treatment of nude mice with 16
was tolerated well and had no signiﬁcant effect on mice body
weight (Fig. 6e). Nude mice were inoculated subcutaneously with
BaF3/FLT3-ITD cells. The control group displayed rapid tumor
growth, while tumor growth in the group treated s.c. with
compound 16 (200 mg kg−1) was delayed and became ﬁrst
apparent on day 11 (Fig. 6f). Tumor growth in the treated group
was reduced to 6% T/C on day 11 and 28% on day 14 proving
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Fig. 5 Activity, target occupancy, and functional effects of STAT5 inhibitor 16 tested in STAT5-dependent cells. a 16 blocks tyrosine phosphorylation of
STAT5 in a dose-dependent manner as shown by western blot analysis in BaF3/FLT3-ITD cells after 6 h treatment. Relative STAT5 phosphorylation levels
were plotted as after quantiﬁcation using Image J software. Immunoblotting for beta-actin was used as a control for uniform protein loading (n= 3).
b Compound 16 inhibits transcriptional activity of STAT5 in BaF3/FLT3-ITD cells as measured by normalized Fluc/Rluc ratio in dual luciferase reporter
assay (n= 3). c Expression of downstream targets of STAT5 Pim1,BcL-xL and Cis was reduced after 18 h of treatment with compound 16. Gene expression
was quantiﬁed by quantitative PCR (n= 3). d Compound 16 inhibits the proliferation of BaF3/FLT3-ITD cells after 48 h as determined by the Alamar Blue
assay (n= 3). e, i BaF3/FLT3-ITD cells were treated with compound 16 after which annexin-V/propidium iodide staining and ﬂow cytometry were
performed (gating strategy as in Supplementary Figure 11a, data shown are one representative of n= 3); (ii) Intracellular levels of phosphorylated STAT5
were evaluated by ﬂow cytometry after 6 h exposure of cells to compound 16 for 50 µM (gating strategy as in Supplementary Figure 11b, data shown are
one representative of n= 3). f–g, In-cell occupancy of STAT5a and STAT5b by compound 16 in BaF3/FLT3-ITD, determined using ITDRF. ITDRF of
compound 16 on STAT5a and STAT5b denaturization at 60 °C for 3min based on raw data from western blotting chemiluminescence readings (n= 3).
CETSA, cellular thermal shift assay; ITDRF, isothermal dose–response ﬁngerprint; OC50, the concentration at which 50% of the STAT5 in the cell was
occupied by inhibitor. For an uncropped image of panels f and g see Supplementary Figure 10. Error bars denote mean ± S.D. and p values are considered as
follows: **p value < 0.01; and ***p value < 0.001. Statistical analyses were performed using one-way ANOVA or the two-tailed Student’s t tests where
appropriate
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07923-2 ARTICLE
NATURE COMMUNICATIONS |           (2019) 10:66 | https://doi.org/10.1038/s41467-018-07923-2 | www.nature.com/naturecommunications 7
Discussion
In this contribution, protein-induced Mannich ligations have
been discovered and characterized as protein-catalyzed, non-
enzymatic reactions following a fundamental mechanism for the
formation and identiﬁcation of protein ligands. The reactions
delivered potent, speciﬁc, and cellularly active inhibitors of the
transcription factor STAT5. The starting point, phosphate-
mimetic fragment 3 was activated by the protein STAT5b-SH2
enabling three-component reactions with FA and various
1H-tetrazoles in aqueous physiological buffer yielding low-
micromolar and submicromolar inhibitors of the
protein–protein interaction site. The progress of the observed
Mannich ligations depended on the pH of the solution and on the
presence of the protein. At pH 7.4, the reaction occurred only in
the presence of the protein, whereas at pH 5.0 it was switched to
an entirely protein-independent reaction. Protein-induced reac-
tions were analyzed using FP and TS assays; products formed
were quantiﬁed by HPLC-MS and protein-induced product was
saturated at 432 nM (average of three independent experiments)
with 250 nM protein. Product saturation is typical for protein-
dependent reactions and resulted from auto-inhibition by the
products formed. The reaction was also inhibited competitively
by alternative ligands of the SH2 domain conﬁrming that the
phosphotyrosine recognition site constituted the catalytic center.
Remarkably, all initial 1H-tetrazole fragments like compound
25 did not bind to the STAT5b-SH2 protein at all (KI > 10 mM),
whereas, for example, the ligation product of 3, FA, and 25,
namely 4-(1H-tetrazol-1-yl)-methylamino-furazan-3-carboxylate
10, displayed super-additive binding with an afﬁnity of 1.4 µM
and the enhanced ligand efﬁciency of 2.23 kJ mol−1 per non-
hydrogen atom. This ﬁndings excluded the mechanism of a
protein-templated reaction, which requires the binding of both
fragments to the protein template in order to initiate the reaction.
Instead, an alternative mechanism of protein-dependent reactions
was observed, in which only one of the starting molecules, here
fragment 3, binds to the protein. Molecular modeling suggested
that H-bonding by the side chain amide of Asn642 induced the
reaction of fragment 3 with FA, that of the intermediary for-
miminium ion with tetrazoles, and the high selectivity of the
reactions21. This hypothesis was challenged by investigating the
protein-dependent reaction of 3, FA, and 1H-tetrazole with the
phosphotyrosine binding site of STAT3-SH2, which is structu-
rally closely related containing Arg618 and Ser622 but lacks
Asn642. Indeed STAT3-SH2 did not catalyze the Mannich liga-
tion reaction and no product was identiﬁed in HPLC-MS. In
agreement with this result, STAT3, STAT1, and the protein tyr-
osine phosphatase SHP2, all lacking the Asn-residue in the
phosphotyrosine recognition sites, did not bind the STAT5
inhibitors 10 and 16, although cross-reactivity has been reported
for other STAT-inhibitors44,45. The importance of Asn642 was
further conﬁrmed by the mutant STAT5b-N642A, which was
generated by site-directed mutagenesis. The mutant protein
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Fig. 6 Synergy of inhibitor 16 and kinase inhibitor midostaurin (PKC412). Activity tested in a murine cancer model. a MV-411 cells were treated with
PKC412 (10 nM) or compound 16 (10 µM) alone or in combination and incubated for 24 h followed by annexin-V/ propidium iodide staining and ﬂow
cytometry. Apoptosis was quantitated for three independent experiments (n= 3) and error bars denote mean ± S.D. b Cell viability assays were carried out
by treating MV-411 cells with compound 16 (10 µM) and PKC412 (10 nM) alone or in combination. The number of viable cells was distinguished using an
ATP-dependent bioluminescence assay (CellTiter-Glo, Promega) (n= 3, error bars denote mean ± S.D.). c Combination index (CI) plot showing the
synergistic effect of compound 16 and PKC412 in MV-411 cells. CI values were generated using CalcuSyn software (Conservion, Ferguson, MO) and plotted
as a function of fractional growth inhibition (n= 3) (Fa) where Fa= (A570 control−A570 treated)/A570control. CI values of < 1,= 1, and > 1 indicate
synergism, additivity, and antagonism, respectively. Error bars denote mean ± S.D. d Relative STAT5 phosphorylation levels were plotted based on the raw
data from western blotting chemiluminescence readings to study the synergistic effect of both compounds on STAT5 phosphorylation reduction. MV-411
cells were treated with compound 16 or PKC412 alone or in combination and incubated for 6 h (n= 3, error bars denote mean ± S.D.). e The corresponding
body weight changes in non-xenografted mice during compound 16 treatments (n= 6, error bars denote mean ± S.D.). f Compound 16 signiﬁcantly inhibits
tumor growth in BaF3/FLT3-ITD xenograft tumor model. Time course of tumor growth suppressed by compound 16 (200mg kg−1) in mice bearing BaF3/
FLT3-ITD tumor (n= 6, error bars denote mean ± S.D.)
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displayed strongly reduced binding afﬁnity to peptide 1 and to
inhibitor 10 and did not catalyze a Mannich ligation reaction as
shown for the wildtype protein. In conclusion, the observed
protein-dependent reaction constitutes indeed a protein-induced
reaction in which the protein catalytically activates the bound
fragment 3 by speciﬁc binding interactions without templating
the reacting fragments priorly.
Speciﬁcity of the formed inhibitors for STAT5 was also con-
ﬁrmed in complex cellular systems. Binding of inhibitors 10 and
16 to STAT5a,b in cell lysates was determined by CETSA. The
high selectivity of the protein-ligand interaction was demon-
strated by the fact that inhibitor 10 in cell lysates suppressed
photo-crosslinking of the biotinylated STAT5 ligand 27 with
STAT5 but not with other proteins. In addition, the selectivity of
compound 16 in living cells was proven by ITDRF. It was found
that 50% of the target proteins STAT5a and b were occupied in
living cells with 16 at concentrations (OC50 values) being in the
same range as the IC50 values observed for the inhibition of
STAT5 phosphorylation and cell proliferation, indicating that the
interaction of 16 with the target STAT5 alone was sufﬁcient to
generate and explain the observed biological effects. Likewise,
compound 16 was able to block STAT5 transcription and to
inhibit cellular proliferation of cancer cells in a mouse model.
Another proof for the cellular selectivity of 16 for STAT5 was that
the proliferation of all tested cell lines which proliferate inde-
pendently from STAT5 activation was not inhibited by 16 and
these cells showed no sign of toxicity.
Our work demonstrates the growing power of protein-
dependent fragment ligations in fragment-based drug discovery.
Protein-induced multicomponent reactions such as Mannich
ligations enlarge the chemical diversity of protein ligands acces-
sible by the method considerably. Protein-induced fragment
ligations seem to be especially advantageous for the formation of
potent and speciﬁc ligands as molecular interactions responsible
for binding catalyze the ligation reaction. Considering the
omnipresence of FA in living cells46,47 and the versatility of
reactions this and other aldehydes can undergo, the mechanism
should ﬁnd broad application on numerous protein targets and
many bioactive fragments should be expandable to chemically
diverse and potent protein ligands, possibly even in living cells.
Thus, protein-induced reactions seem to constitute an additional,
non-enzymatic mechanism exerted by proteins enabling the
molecular evolution of ligands and modulating protein activities
and functions.
Methods
General methods. Protocols and reaction schemes for the chemical synthesis of
compounds 1–27 as well as other methodological information are reported in
the Supplementary Methods. Identity and purity ( > 95%) of all compounds were
determined by chromatography (silica or RP-18 HPLC), by fully assigned 1H-
and 13C-NMR spectra, by high-resolution mass spectra and by elemental
analysis.
Antibodies and reagents. The following antibodies were used for immunoblot-
ting: anti-STAT5a (C-6, cat. sc271542, 1 µg ml−1) and STAT5b (G-2, cat. sc-1656,
1 µg ml−1), anti-STAT3 (C-20, cat. sc-482, 1 µg ml−1), anti-phospho-STAT3
(Tyr 705) (cat. sc-7993, 1 µg ml−1), anti-STAT5 (C-17, cat. sc-835, 1 µg ml−1), and
anti-Bcl-xL (H-5, cat. sc-8392, 1 µg ml−1) were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA). Antibodies recognizing Cyclin D1 (92G2, cat. 2978 s,
2 µg ml−1), FLT3 (8F2, cat. 3462 s, 1 µg ml−1), phospho-STAT5 (Tyr694) (cat.
9351, 1 µg ml−1), phospho-FLT3 Tyr591 (cat. 3461 s, 1 µg ml−1) were obtained
from Cell Signaling Technology (Danvers, MA). Anti-Pim1 (M08, clone 1C10, cat.
H00005292-M08, 2 µg ml−1) was purchased from Abnova (Taiwan), anti-Beta-
actin (cat. ab8227, 0.5 µg ml−1) was from Abcam (Cambridge, MA), anti
Biotin−Peroxidase antibody (cat. A4541, 1 µg ml−1) was obtained from Sigma-
Aldrich (Taufkirchen, Germany) and anti-CIS (cat. PA5–27128, 1 µg ml−1) was
from Thermo Fisher Scientiﬁc (Braunschweig, Germany). For phospho ﬂow
cytometry experiments, PE-Cy™7 mouse anti-Stat5 (pY694) (clone 47, cat. 560117,
20 µl each test) and anti-mouse IgG1 monoclonal antibody (clone A85-1, cat.
550083, 0.2 µg ml−1) were from BD Biosciences. Antibodies were validated by the
manufacturers. Recombinant mouse IL3 protein (cat. PMC0034, 1 ng ml−1) was
purchased from Thermo Fisher Scientiﬁc and midostaurin hydrate (PKC412, cat.
M1323) was from Sigma-Aldrich. Both TransAM STAT family kit (cat. 42296) and
nuclear extraction kit (cat. 40010) were from Active Motif (Carlsbad, CA, USA).
Cell lines and cell culture. MV-411 (CRL-9591) and K562 (CCL-243) cells were
from American Type Culture Collection (ATCC), (LGC Standards GmbH, Wesel,
Germany). BaF3 and BaF3/FLT3-ITD cells were kind gifts from professor Carol
Stocking (University Hospital Hamburg-Eppendorf). All suspension cells were
cultured in Rosewell Park Memorial Institute media supplemented with 10% fetal
calf serum (FCS) without or without recombinant mouse IL3 (1 ng ml−1). COS-7
(CRL-1651), HeLa (CCL-2), MDA-MB-231 (HTB-26), and HT-29 (HTB-38) were
from and certiﬁed by ATCC and cultured in DMEM media supplemented with
10% FCS. Cell culture media and FCS were purchased from Biozol (Biozol, Eching,
Germany). Cells were incubated at 37 °C, 5% CO2 atmosphere. All cell lines were
tested and were mycoplasma-free using MycoAlert Mycoplasma Detection Kit
(Lonza).
Detection of protein-induced ligand formation via FP assay. All FP assays were
conducted in a total volume of 20 µl in 50 mM of MOPS buffer (pH 7.4) at room
temperature. For investigating the tolerance of the assay for FA, serial dilutions of
FA (concentration range: 0–1 mM) were prepared and incubated with 250 nM of
MBP-STAT5b in buffer. For the protein-induced reaction, 250 nM of MBP-STAT5b
protein were added to a mixture of 250 µM of 3 and one heteraryl nucleophile per
microtiter plate well with increasing concentration of FA up to the concentration of
250 µM. Reaction mixtures were incubated for 12 h with mild shaking. Plates were
centrifuged and 10 nM of FP probe 1 were added and incubated for 1 h with mild
shaking before measurement with Saﬁre2 well plate reader (Tecan, Crailsheim,
Germany).
Detection of protein-induced ligand formation via TSA. Here we introduced the
possibility of using TSA48 assay to determine protein-induced ligand formation.
The compatibility of FA with the TSA was investigated using MBP-STAT5b-SH2
protein (500 nM) mixed with increasing concentrations of FA up to the con-
centration of 250 µM and incubated at room temperature with mild shaking in a
sealed 384 PCR plate. To determine the formation of ligand via a protein-induced
reaction, MBP-STAT5b-SH2 protein 500 nM was added to 250 µM (IC20) 4-amino-
furazane-3-carboxylic acid 3, equimolar amount (250 µM) of one heteraryl
nucleophile per PCR plate well with increasing concentration of FA up to the
concentration of 250 µM. Reaction mixtures were incubated for 12 h with mild
shaking at room temperature, respectively. After 12 h, the plates were centrifuged
and 1 µl of 400X Sypro Orange solution (Thermo Scientiﬁc) was added, resulting in
a total assay volume of 20 µl, with a ﬁnal protein concentration of 475 nM. The PCR
plates were again sealed with optical seal, shaken for 15 min, and centrifuged.
Thermal scanning (20–95 °C at 1 °Cmin−1) was performed using a real-time PCR
setup (LightCycler (Roche Diagnostics, Mannheim, Germany) and ﬂuorescence
intensity was measured after every 0.3 s. Curve ﬁtting, melting temperature cal-
culation, and report generation on the raw data were performed using GraphPad
Prism 5 software.
Detection of protein-induced ligand formation by LC/MS. Extracted ion
chromatography was performed with reaction mixtures containing 250 nM of
MBP-STAT5b protein, 250 µM (IC20) 4-amino-furazane-3-carboxylic acid 3,
equimolar amount (250 µM) of one heteraryl nucleophile and FA with a total
volume of 100 µl. The reaction mixtures were vortexed to mix thoroughly and
incubated overnight at room temperature and was analyzed using a HPLC/QTOF-
MS instrument by Agilent, consisting of an Inﬁnity 1290 UHPLC coupled to a 6550
iFunnel QTOF. After 12 h each sample was analyzed in triplicate by injecting
(10 μl) into the LC/MS instrument and the ligation products were identiﬁed by
their molecular weights and by comparison of the retention times of synthetic
reference. Calibration curves for hit compounds 10 and 16 are given in Supple-
mentary Figure 19.
Determination of STAT-DNA binding using ELISA. Binding of STAT1, STAT3,
STAT5a, and b to DNA was determined from nuclear protein extracts using the
TransAM STAT family kit from Active Motif (Carlsbad, CA). Nuclear protein
extract was prepared by resuspending nuclear pellet by pipetting up and down in
50 µl of complete lysis buffer (Active Motif, Carlsbad,CA) in the presence of 2.5 µl
of detergent to ease solubilization of membrane associated nuclear proteins. Sus-
pension was incubated on ice for 30 min on a rocking platform at 150 rpm followed
by 30 s vortex at highest setting. Nuclear extract fraction was collected through
centrifugation at 14,000×g and protein concentration was determined using
Bradford assay. Nuclear extract (2 µl of a 1 µg µl−1 solution) containing activated,
dimeric STAT was dissolved in a mixture of a solution of the inhibitor 3, 10, or 16
in complete lysis buffer (20 μl, 1% (v/v) DMSO) and complete binding buffer
(30 μl) in microtiter wells coated with DNA of the respective STAT consensus
sequence. After incubation at room temperature for 1 h, the wells were washed
three times with the wash buffer and incubated with respective STAT antibodies
for 1 h. After washing as before, wells were incubated with a secondary antibody
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conjugated to horseradish peroxidase for 1 h at room temperature. Wells were
washed again for three times, incubated with 100 μl of developing solution,
quenched with 100 μl of the stop solution, and the absorbance was measured at
450 nm using Saﬁre2 well plate reader (Tecan, Crailsheim, Germany).
EMSA. Gel shift assay was conducted using a double-stranded, biotin-labeled
oligonucleotide probe containing the consensus binding site for STAT5 (sense
strand, 5′-AGATTTCTAGGAATTCAATCC-3′), using the Gelshift Chemilumi-
nescent EMSA kit (Active Motif). In brief, protein–DNA complexes were resolved
on a nondenaturing polyacrylamide gel, transferred to a positively charged nylon
membrane, and cross-linked to the membrane using the UV-light cross-linker.
After blocking, the membrane was incubated with blocking buffer containing
streptavidin conjugated to HRP. After washing, protein–DNA complexes
were detected using a chemiluminescent substrate (Active Motif, Carlsbad, CA,
USA)40,49.
Photo-crosslinking and enrichment of biotinylated proteins. Peptide probe
27 (100 µM) was incubated with BaF3/FLT3-ITD whole cell lysates (1 ml of 1 mg
ml−1) in the binding buffer (50 mM HEPES, pH 7.5, 200 mM NaCl, 2 mM
MgCl2, 0.1% Tween-20, 20% glycerol, 2 mM phenylmethylsulfonyl ﬂuoride, Roche
Complete ethylenediaminetetraacetic acid-free protease inhibitor cocktail) for 1 h
at 4 °C. The samples were then irradiated at 365 nM using a UV transilluminator for
15 min at 4 °C. For competitive displacement studies, compound 10 (50 µM) was
added together with peptide probe 27 and incubated with whole cell lysates for 1 h
at 4 °C prior to UV photo-crosslinking for 15 min at 4 °C. The mixture was then
incubated with Neutravidin agarose resin (Thermo Fisher Scientiﬁc) for 2 h at
room temperature. After washing with phosphate-buffered saline with 0.1%
sodium dodecyl sulfate (SDS), the enriched proteins were eluted by boiling the
beads in SDS-polyacrylamide gel electrophoresis sample buffer.
Statistical analysis. Statistical calculations were performed using GraphPad Prism
5.01 software and reported as mean ± S.D. Experiments were performed in tripli-
cates and/or repeated at least three times unless indicated otherwise. Two-tailed
Student’s t tests and one-way analysis of variance were used to identify statistically
signiﬁcant data. p values are considered as follows: *p value < 0.05; **p value < 0.01;
and ***p value < 0.001 and statistical signiﬁcance was attributed to p values < 0.05.
Synergy in cell viability assays was determined by plotting isobolograms and cal-
culating the CI using CalcuSyn software (Calcusyn software, Biosoft, San Diego,
CA, USA) (Conservion, Ferguson, MO) using the Chou–Talalay method43 to
ascertain if the effects of drug combinations were synergistic (CI < 1), additive (CI
= 1), or antagonistic (CI > 1).
Animal experiments. NSG mice (NOD/Shi-scid/IL-2Rγnull) obtained from The
Jackson Laboratory aged 6 weeks with an average body weight of 22 g. All animal
experiments have been approved by the Tierversuchskommission (commission for
animal experiments) of the Landesamt für Gesundheit und Soziales (LaGeSo, the
state ofﬁce for health and social affairs), which is the responsible ethics committee
for all animal experiments conducted in the state of Berlin. All animal experiments
were carried out in accordance with the United Kingdom coordinating committee
on cancer research regulations for the welfare of animals and with German Animal
Protection Law and were reviewed by the animal protection ofﬁcer (Tierschutz-
beauftragter) at Experimental Pharmacology & Oncology (EPO) Berlin-Buch
GmbH. BaF3/FLT3-ITD cells were injected into mice subcutanously (106 cells per
mouse). Inoculated and control mice (six in each group) were treated for 16 d once
daily s.c. with either the vehicle (10% (v/v) DMSO/0.25% Tween 80) or compound
16 (200 mg kg−1) dissolved in vehicle, starting shortly after tumor cell inoculation.
Former studies had shown that this concentration of test compound is well tol-
erated by the mice. Tumor volumes and body weights were recorded daily (n= 6,
error bars denote mean ± S.D.).
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
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